Developer docs
API playgroundTry for free, no card

Search company profiles

WuXi AppTec

Full company profile

uuid0000ca7

Namestring
WuXi AppTec
Legal namestring
WuXi AppTec Co., Ltd.
Websiteurl
wuxiapptec.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

WuXi AppTec Co., Ltd., founded in 2000 and headquartered in Shanghai, is a publicly listed (Shanghai 603259.SH, Hong Kong 2359.HK) global Contract Research, Development, and Manufacturing Organization (CRDMO) serving pharmaceutical and biotechnology companies across more than 30 countries. The company operates an integrated, end-to-end platform organized into three core segments: WuXi Chemistry (small molecule, oligonucleotide, peptide, and complex conjugate CRDMO services from discovery through commercial manufacturing), WuXi Biology (target discovery to candidate selection, staffed by nearly 3,000 scientists), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC services). Sub-brands such as TIDES (oligonucleotides/peptides) and WuXi STA (small molecule drug substance and drug product) extend modality coverage. Manufacturing capacity includes over 4,000 kL of small molecule API reactor volume and over 100,000 L of Solid Phase Peptide Synthesizer capacity across 20+ facilities in Asia, Europe, and North America, with a 3,452-molecule D&M pipeline (83 commercial, 91 Phase III) as of year-end 2025.

The business model is a project-based, multi-year B2B professional services model in which WuXi follows a molecule from early discovery through commercial manufacturing, generating revenue at each stage. Customers include large pharmaceutical companies (e.g., Eli Lilly, for which WuXi produces the Zepbound active ingredient), mid-size pharma, and biotech startups, with a total active customer base exceeding 6,000. WuXi and its biologics affiliate are estimated to be embedded in roughly 25% of drugs used in the United States, and approximately 65% of WuXi revenue is U.S.-derived. In FY2025 the company recorded total revenue of RMB 45.46 billion (+15.8% YoY) and adjusted non-IFRS net profit of RMB 14.96 billion (+41.3% YoY), with Q1 2026 revenue of RMB 12.44 billion (+28.8% YoY) and a backlog of RMB 59.77 billion (+23.6% YoY) as of March 2026. Quality systems are validated across FDA, EMA, NMPA, and PMDA inspections, with 741 audits and inspections passed in 2025.

A defining strategic context is the June 8, 2025 designation of WuXi AppTec by the U.S. Department of Defense under Section 1260H of the National Defense Authorization Act as a Chinese military company, which the company is contesting through a June 11, 2026 lawsuit in the U.S. District Court for the District of Columbia. The designation carries downstream implications under the BIOSECURE Act for federal procurement and existing contracts, with a five-year transition window; WuXi is responding with U.S. capacity expansion (Middletown, Delaware, online by end of 2026), continued multi-jurisdictional capacity build, and inorganic moves such as the 2026 acquisition of Dongyao Pharmaceutical.

Short descriptiontext

WuXi AppTec is a global CRDMO offering integrated pharmaceutical research, development, and manufacturing services across small molecules, oligonucleotides, peptides, and biologics, serving more than 6,000 pharma and biotech customers in 30+ countries from facilities in Asia, Europe, and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, pharmaceutical manufacturing services, drug development services, small molecule CDMO, biologics contract services
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Testing Laboratories8734
Product category
Pharmaceutical Contract Manufacturing Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CRDMO Services Revenue
TypeProfessional Services
Description

WuXi AppTec generates revenue through providing integrated Contract Research, Development and Manufacturing services. Revenue streams include chemistry services, biology services, testing services, and manufacturing services. The company operates on a project-based fee-for-service model with 'follow the molecule' strategy, generating revenue from early discovery projects that progress through development to commercial manufacturing.

wuxiapptec.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based custom pricing for pharmaceutical R&D and manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by project scope, molecule complexity, service type (discovery, development, manufacturing), volume requirements, and contract duration

wuxiapptec.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1WuXi Chemistry
Description

Provides Contract Research, Development and Manufacturing Organization (CRDMO) services for new drug development from discovery to commercial, covering small molecules, oligonucleotides, peptides and complex conjugates.

wuxiapptec.com
+4 more records
Core offering1 text field

WuXi AppTec is a global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated, end-to-end pharmaceutical R&D and manufacturing services. Its offerings span early drug discovery, preclinical and clinical development, testing (DMPK, toxicology, bioanalytical, CMC), and commercial-scale API and drug product manufacturing across small molecules, oligonucleotides, peptides, and biologics for pharmaceutical and biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Revenue growth of 28.8% YoY to RMB 12.44 billion in Q1 2026
+5 more records
Product overview1 text field

WuXi AppTec is a Contract Research, Development, and Manufacturing Organization (CRDMO) that offers an integrated, end-to-end platform spanning Research (R), Development (D), and Manufacturing (M) for pharmaceutical and biotech companies. The platform is organized into three core business segments: WuXi Chemistry (small molecule, oligonucleotide, and peptide CRDMO), WuXi Biology (discovery services from target identification to candidate selection), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC testing). The TIDES CRDMO brand specifically addresses oligonucleotides and peptides. The company operates across Asia, Europe, and North America, with major U.S. facilities in San Diego, Middletown (DE), Cranbury (NJ), and Natick (MA). WuXi AppTec's model is designed to eliminate handoffs between drug development stages, enabling customers to progress molecules from early discovery through commercial manufacturing under one quality system.

Product and service5 records
1WuXi Chemistry
CategoryCRDMO Services
Description

Provides Contract Research, Development, and Manufacturing Organization (CRDMO) services for new drug development from discovery through commercial supply, covering all synthetic molecular modalities including small molecules, oligonucleotides, peptides, and complex conjugates.

2WuXi Biology
CategoryDrug Discovery Services
Description

Provides a full spectrum of biology services and solutions supporting stand-alone and integrated projects, from target discovery to candidate selection and into the clinic, staffed by nearly 3,000 scientists covering all major disease areas and therapeutic modalities.

3WuXi Testing
CategoryLaboratory Testing Services
Description

Integrated testing platform across the full life cycle of drug discovery and development, providing DMPK (drug metabolism and pharmacokinetics), toxicology, bioanalytical services, and CMC support to help customers deliver innovative medicines to patients.

4TIDES CRDMO
CategorySpecialized CDMO Services
Description

Provides integrated discovery, development, and manufacturing services for oligonucleotides and peptides, offering the entire supply chain in one organization to address complex challenges in these rapidly growing therapeutic modalities.

5WuXi STA
CategoryPharmaceutical Manufacturing
Description

Small molecule drug substance (API) and drug product manufacturing services delivered at U.S. sites including San Diego, CA and Middletown, DE, under the WuXi STA brand, with FDA-inspected facilities.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOthers
Description

WuXi AppTec is a participant in the United Nations Global Compact, supporting its ten principles across human rights, labor, environment, and anti-corruption areas

Strategic tierCoreTypeOthers
Description

WuXi AppTec serves as a supplier partner to PSCI, promoting responsible pharmaceutical supply chain practices

Strategic tierCoreTypeStrategic or Co-development Partner
Description

WuXi AppTec produces the active ingredient for Eli Lilly's obesity drug Zepbound. Approximately $30.4 billion in US revenue could be at risk during 2027 to 2030 due to Pentagon designation, with existing customers given five years to wind down contracts

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sister company under WuXi group offering biologics-focused CRDMO services. Highly comparable end-to-end model for the biologics subset of WuXi AppTec's pipeline.

TypeDirect peer
Description

Swiss-headquartered global CDMO leader in small molecules, biologics, and cell & gene therapy. Closest Western competitor with comparable integrated CDMO footprint and scale.

TypeDirect peer
Description

U.S.-based CDMO specializing in drug product, biologics, and oral solid dose manufacturing. Direct competitor for late-stage small molecule and biologics CDMO work.

TypeDirect peer
Description

Korean-based biologics CDMO rapidly scaling large-scale mammalian manufacturing capacity. Competes for biologics programs WuXi wins in the global outsourcing market.

TypeBroad incumbent
Description

Large CRO with significant R&D services business including labs, clinical, and biotech funding. Broader incumbent that overlaps with WuXi's research and discovery offerings.

TypeDirect peer
Description

U.S.-based CRO/CDMO with strong discovery, preclinical, and biologics manufacturing. Closely comparable on the discovery and testing services side of WuXi's CRDMO model.

TypeDirect peer
Description

Global CRO offering clinical and laboratory services. Adjacent peer for the preclinical, bioanalytical, and central lab testing segments.

TypeBroad incumbent
Description

German bioprocessing equipment and services supplier. Comparable as a scaled player in the biopharma services value chain, though focused upstream on equipment and consumables.

TypeBroad incumbent
Description

Diversified life sciences giant with a PPD clinical/CRO business and extensive biopharma services. Broad incumbent serving many of the same pharma customers across multiple service lines.

TypeEmerging player
Description

Global bioanalytical and laboratory testing services provider. Most comparable peer to WuXi Testing's DMPK, toxicology, and bioanalytical service lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment50 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WuXi AppTec

Pharmaceutical Contract Manufacturing Serviceswuxiapptec.com

WuXi AppTec is a global CRDMO offering integrated pharmaceutical research, development, and manufacturing services across small molecules, oligonucleotides, peptides, and biologics, serving more than 6,000 pharma and biotech customers in 30+ countries from facilities in Asia, Europe, and North America.

What WuXi AppTec does

WuXi AppTec Co., Ltd., founded in 2000 and headquartered in Shanghai, is a publicly listed (Shanghai 603259.SH, Hong Kong 2359.HK) global Contract Research, Development, and Manufacturing Organization (CRDMO) serving pharmaceutical and biotechnology companies across more than 30 countries. The company operates an integrated, end-to-end platform organized into three core segments: WuXi Chemistry (small molecule, oligonucleotide, peptide, and complex conjugate CRDMO services from discovery through commercial manufacturing), WuXi Biology (target discovery to candidate selection, staffed by nearly 3,000 scientists), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC services). Sub-brands such as TIDES (oligonucleotides/peptides) and WuXi STA (small molecule drug substance and drug product) extend modality coverage. Manufacturing capacity includes over 4,000 kL of small molecule API reactor volume and over 100,000 L of Solid Phase Peptide Synthesizer capacity across 20+ facilities in Asia, Europe, and North America, with a 3,452-molecule D&M pipeline (83 commercial, 91 Phase III) as of year-end 2025.

The business model is a project-based, multi-year B2B professional services model in which WuXi follows a molecule from early discovery through commercial manufacturing, generating revenue at each stage. Customers include large pharmaceutical companies (e.g., Eli Lilly, for which WuXi produces the Zepbound active ingredient), mid-size pharma, and biotech startups, with a total active customer base exceeding 6,000. WuXi and its biologics affiliate are estimated to be embedded in roughly 25% of drugs used in the United States, and approximately 65% of WuXi revenue is U.S.-derived. In FY2025 the company recorded total revenue of RMB 45.46 billion (+15.8% YoY) and adjusted non-IFRS net profit of RMB 14.96 billion (+41.3% YoY), with Q1 2026 revenue of RMB 12.44 billion (+28.8% YoY) and a backlog of RMB 59.77 billion (+23.6% YoY) as of March 2026. Quality systems are validated across FDA, EMA, NMPA, and PMDA inspections, with 741 audits and inspections passed in 2025.

A defining strategic context is the June 8, 2025 designation of WuXi AppTec by the U.S. Department of Defense under Section 1260H of the National Defense Authorization Act as a Chinese military company, which the company is contesting through a June 11, 2026 lawsuit in the U.S. District Court for the District of Columbia. The designation carries downstream implications under the BIOSECURE Act for federal procurement and existing contracts, with a five-year transition window; WuXi is responding with U.S. capacity expansion (Middletown, Delaware, online by end of 2026), continued multi-jurisdictional capacity build, and inorganic moves such as the 2026 acquisition of Dongyao Pharmaceutical.

WuXi AppTec firmographics

Firmographics
Name
WuXi AppTec
Legal name
WuXi AppTec Co., Ltd.
Website
https://wuxiapptec.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
10,001+ employees
Short description
WuXi AppTec is a global CRDMO offering integrated pharmaceutical research, development, and manufacturing services across small molecules, oligonucleotides, peptides, and biologics, serving more than 6,000 pharma and biotech customers in 30+ countries from facilities in Asia, Europe, and North America.
Ownership category
akta.pro rank

WuXi AppTec industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Contract research organization
  • Pharmaceutical manufacturing services
  • Drug development services
  • Small molecule CDMO
  • Biologics contract services

Where WuXi AppTec is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices9 records

Markets served

WuXi AppTec business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. CRDMO Services Revenue: WuXi AppTec generates revenue through providing integrated Contract Research, Development and Manufacturing services. Revenue streams include chemistry services, biology services, testing services, and manufacturing services. The company operates on a project-based fee-for-service model with 'follow the molecule' strategy, generating revenue from early discovery projects that progress through development to commercial manufacturing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based custom pricing for pharmaceutical R&D and manufacturing services

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

WuXi AppTec product offering

Product offering

Core offering

WuXi AppTec is a global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated, end-to-end pharmaceutical R&D and manufacturing services. Its offerings span early drug discovery, preclinical and clinical development, testing (DMPK, toxicology, bioanalytical, CMC), and commercial-scale API and drug product manufacturing across small molecules, oligonucleotides, peptides, and biologics for pharmaceutical and biotech customers.

Product overview

WuXi AppTec is a Contract Research, Development, and Manufacturing Organization (CRDMO) that offers an integrated, end-to-end platform spanning Research (R), Development (D), and Manufacturing (M) for pharmaceutical and biotech companies. The platform is organized into three core business segments: WuXi Chemistry (small molecule, oligonucleotide, and peptide CRDMO), WuXi Biology (discovery services from target identification to candidate selection), and WuXi Testing (DMPK, toxicology, bioanalytical, and CMC testing). The TIDES CRDMO brand specifically addresses oligonucleotides and peptides. The company operates across Asia, Europe, and North America, with major U.S. facilities in San Diego, Middletown (DE), Cranbury (NJ), and Natick (MA). WuXi AppTec's model is designed to eliminate handoffs between drug development stages, enabling customers to progress molecules from early discovery through commercial manufacturing under one quality system.

Differentiator

Problem solved

Functional benefit

Brands

  • WuXi Chemistry: Provides Contract Research, Development and Manufacturing Organization (CRDMO) services for new drug development from discovery to commercial, covering small molecules, oligonucleotides, peptides and complex conjugates.
  • WuXi Biology
  • WuXi Testing
  • WuXi STA
  • TIDES

Products and services

  • WuXi Chemistry Provides Contract Research, Development, and Manufacturing Organization (CRDMO) services for new drug development from discovery through commercial supply, covering all synthetic molecular modalities including small molecules, oligonucleotides, peptides, and complex conjugates.
  • WuXi Biology Provides a full spectrum of biology services and solutions supporting stand-alone and integrated projects, from target discovery to candidate selection and into the clinic, staffed by nearly 3,000 scientists covering all major disease areas and therapeutic modalities.
  • WuXi Testing Integrated testing platform across the full life cycle of drug discovery and development, providing DMPK (drug metabolism and pharmacokinetics), toxicology, bioanalytical services, and CMC support to help customers deliver innovative medicines to patients.
  • TIDES CRDMO Provides integrated discovery, development, and manufacturing services for oligonucleotides and peptides, offering the entire supply chain in one organization to address complex challenges in these rapidly growing therapeutic modalities.
  • WuXi STA Small molecule drug substance (API) and drug product manufacturing services delivered at U.S. sites including San Diego, CA and Middletown, DE, under the WuXi STA brand, with FDA-inspected facilities.

Quantifiable outcome

  • Revenue growth of 28.8% YoY to RMB 12.44 billion in Q1 2026
  • +5 more outcomes

Companies that use WuXi AppTec

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

WuXi AppTec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

WuXi AppTec partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • United Nations Global Compact (UNGC)coreOthersWuXi AppTec is a participant in the United Nations Global Compact, supporting its ten principles across human rights, labor, environment, and anti-corruption areas
  • Pharmaceutical Supply Chain Initiative (PSCI)coreOthersWuXi AppTec serves as a supplier partner to PSCI, promoting responsible pharmaceutical supply chain practices
  • Eli LillycoreStrategic or Co-development PartnerWuXi AppTec produces the active ingredient for Eli Lilly's obesity drug Zepbound. Approximately $30.4 billion in US revenue could be at risk during 2027 to 2030 due to Pentagon designation, with existing customers given five years to wind down contracts

Scale indicators13 records

Recent moves11 records

Expansion highlights5 records

WuXi AppTec competitors and assessment

Company assessment

Direct peers

  • WuXi Biologics: Sister company under WuXi group offering biologics-focused CRDMO services. Highly comparable end-to-end model for the biologics subset of WuXi AppTec's pipeline.
  • Lonza Group: Swiss-headquartered global CDMO leader in small molecules, biologics, and cell & gene therapy. Closest Western competitor with comparable integrated CDMO footprint and scale.
  • Catalent: U.S.-based CDMO specializing in drug product, biologics, and oral solid dose manufacturing. Direct competitor for late-stage small molecule and biologics CDMO work.
  • Samsung Biologics: Korean-based biologics CDMO rapidly scaling large-scale mammalian manufacturing capacity. Competes for biologics programs WuXi wins in the global outsourcing market.
  • Charles River Laboratories: U.S.-based CRO/CDMO with strong discovery, preclinical, and biologics manufacturing. Closely comparable on the discovery and testing services side of WuXi's CRDMO model.
  • ICON plc: Global CRO offering clinical and laboratory services. Adjacent peer for the preclinical, bioanalytical, and central lab testing segments.

Broad incumbents

  • IQVIA Holdings: Large CRO with significant R&D services business including labs, clinical, and biotech funding. Broader incumbent that overlaps with WuXi's research and discovery offerings.
  • Sartorius AG: German bioprocessing equipment and services supplier. Comparable as a scaled player in the biopharma services value chain, though focused upstream on equipment and consumables.
  • Thermo Fisher Scientific: Diversified life sciences giant with a PPD clinical/CRO business and extensive biopharma services. Broad incumbent serving many of the same pharma customers across multiple service lines.

Emerging players

  • Eurofins Scientific: Global bioanalytical and laboratory testing services provider. Most comparable peer to WuXi Testing's DMPK, toxicology, and bioanalytical service lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

WuXi AppTec social profiles

Digital presence

WuXi AppTec compliance and trust

Trust signal

Compliance2 records

WuXi AppTec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WuXi AppTec leadership team

Management profile

Number of profiles

Profiles11 records

WuXi AppTec subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

WuXi AppTec funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WuXi AppTec M&A and investment

M&A and investment

M&A6 records

Investments50 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WuXi AppTec

What does WuXi AppTec do?

WuXi AppTec is a global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides integrated, end-to-end pharmaceutical R&D and manufacturing services. Its offerings span early drug discovery, preclinical and clinical development, testing (DMPK, toxicology, bioanalytical, CMC), and commercial-scale API and drug product manufacturing across small molecules, oligonucleotides, peptides, and biologics for pharmaceutical and biotech customers.

Is WuXi AppTec a public or private company?

WuXi AppTec is a public company. It is classified as public and is currently operating.

When was WuXi AppTec founded?

WuXi AppTec was founded in 2000. It employs 10,001+ people.

Where is WuXi AppTec based?

WuXi AppTec is headquartered in Shanghai, China, in the Asia region.

How does WuXi AppTec make money?

One revenue line is on record: CRDMO Services Revenue.

Who are WuXi AppTec's main competitors?

Direct peers on record are WuXi Biologics, Lonza Group, Catalent, Samsung Biologics, Charles River Laboratories and ICON plc. Broad incumbents are IQVIA Holdings, Sartorius AG and Thermo Fisher Scientific. Eurofins Scientific is listed as an emerging player.

Does WuXi AppTec have an API?

No public API is recorded for WuXi AppTec.

What industry is WuXi AppTec in?

WuXi AppTec's product category is Pharmaceutical Contract Manufacturing Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
36krCXO Leaders Join the AI Poker Table: How Top Executives Are Shaping Enterprise AI StrategiesWuXi AppTec shifted from denying AI drug development to partnering with AI firms like Boltz, which uses its synthesizable chemical assets. Other CXOs like GenScript and Pharmaron are investing in automated wet labs, with AI revenue growing. The industry is moving toward a symbiotic division of labor between AI creativity and CXO physical verification.MoomooHong Kong Stock Market Update | JW Therapeutics-B (02126) rebounds over 8%; company clarifies cost controversy, projects unit production cost of Ruunoda to drop by more than 65% starting next yearWuXi AppTec Juno-B stock rebounded over 8% to HK$2.465 on November 18. The company clarified that Bennaoda's national reimbursement standard is RMB 288,600 effective January 1, 2027, and expects per-unit production costs to drop by more than 65% starting 2027.MoomooHong Kong Stock Market Update | JW Therapeutics-B (02126) Falls More Than 9% Again; CAR-T Drug Price Cut by RMB 1 Million for National Reimbursement; Plans to Raise HKD 160 Million via Share Placement at a 2.97% DiscountWuXi AppTec's stock fell over 9% after its CAR-T drug Breyanzi was added to the national reimbursement list with a price cut to RMB 288,600 per dose. The company raised HK$160 million via a share placement at a 2.97% discount, planning to allocate funds to R&D and manufacturing.MoomooWuxi Apptec (02359): Court Approves Dismissal of Section 1260H LitigationWuxi Apptec and the Department of Defense filed a joint stipulation to dismiss with prejudice the Section 1260H litigation in U.S. District Court for the District of Columbia. The court approved the stipulation on November 16, 2026, withdrawing the lawsuit seeking removal from the list. The company thanked its team and customers and will continue its ethical business practices.MoomooHong Kong Stock Market Update | Innovative Drug Concept Stocks Decline Again; WuXi Juno (02126) Denies 'Selling at a Loss for Publicity'; Institutions Bullish on Hospital Volume Growth for Innovative DrugsInnovative drug concept stocks fell again, with WuXi AppTec Juno down 10.20% to HK$2.42. The company denied selling its CAR-T drug below cost for publicity, citing prudent pricing for volume growth. Guojin Securities expects hospital uptake of innovative drugs to rise in 2027.JiemianWuXi AppTec denies "losing money to gain popularity": opening up volume space based on a profitable price.WuXi AppTec denied that its CAR-T drug price cut into the basic medical insurance directory is 'losing money to gain attention,' calling it a prudent decision that opens volume space at a profitable price. The company expects unit production costs to fall over 65% due to domestic substitution and scale effects, and estimates current capacity will meet 2027 demand.JiemianThe cancer drug "Million Yuan Injection" has finally entered the medical insurance catalog, and the number of users is expected to exceed ten thousand.WuXi AppTec's CAR-T therapy Rukiyolun was added to China's National Basic Medical Insurance Directory, effective January 1, 2027, after being in the Commercial Insurance Innovative Drug Directory. The price is expected to drop to about 300,000 yuan, and patient numbers are projected to exceed 10,000, up from under 1,000 in 2025.SohuThe exorbitantly priced medicine originally costing 1.29 million yuan per unit is now covered by medical insurance.On November 14, the National Healthcare Security Administration added WuXi AppTec's CAR-T drug Rigidronase to the medical insurance catalog. The price fell from 1.29 million yuan per dose to below 300,000 yuan. The drug's 5-year disease-free survival rate for lymphoma patients can reach over 60%.SohuThe originally priced 1.29 million yuan per unit expensive medicine is now included in the medical insurance.WuXi AppTec's CAR-T drug Rukiyolunase was added to China's medical insurance catalog on November 14, with its price dropping from 1.29 million yuan to below 300,000 yuan per dose. The drug's 5-year disease-free survival rate for lymphoma patients can reach about 40% as a last-line therapy. This marks the first time CAR-T drugs entered the negotiation phase for basic medical insurance.